A number of firms have modified their ratings and price targets on shares of GlycoMimetics (NASDAQ: GLYC) recently:

  • 12/20/2017 – GlycoMimetics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $21.00 price target on the stock.
  • 12/14/2017 – GlycoMimetics had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $23.00 price target on the stock.
  • 12/12/2017 – GlycoMimetics had its price target raised by analysts at SunTrust Banks, Inc. to $32.00. They now have a “buy” rating on the stock.
  • 12/6/2017 – GlycoMimetics had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 12/6/2017 – GlycoMimetics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/13/2017 – GlycoMimetics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock. According to Zacks, “GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. “
  • 10/26/2017 – GlycoMimetics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $16.00 price target on the stock.
  • 10/23/2017 – GlycoMimetics is now covered by analysts at Roth Capital. They set a “buy” rating and a $25.00 price target on the stock.

GlycoMimetics Inc (NASDAQ:GLYC) opened at $15.68 on Thursday. GlycoMimetics Inc has a 12 month low of $3.82 and a 12 month high of $18.25.

GlycoMimetics (NASDAQ:GLYC) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04. sell-side analysts anticipate that GlycoMimetics Inc will post -1.12 earnings per share for the current fiscal year.

In other GlycoMimetics news, SVP Helen M. Thackray sold 2,000 shares of the business’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $15.01, for a total value of $30,020.00. Following the completion of the transaction, the senior vice president now directly owns 148,615 shares of the company’s stock, valued at $2,230,711.15. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 43.80% of the company’s stock.

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Receive News & Ratings for GlycoMimetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.